Furthermore, the injection of SVF via the portal vein significantly reduced thioacetamide-induced liver fibrosis, with lower mRNA levels of IL-1β, IL-6, and TNF-α compared to the ASC and PBS-injected groups. The gene discussed is IL6; the disease is Hepatic fibrosis.